Please login to the form below

Not currently logged in
Email:
Password:

Pearl Therapeutics

This page shows the latest Pearl Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: AstraZeneca's new San Fran hoKeytruda triumphs again, Novo branches out

The state-of-the-art labs bring together researchers from four parts of the AZ family – the 2013-acquired Pearl Therapeutics, 2015- acquired Acerta Pharma, plus MedImmune, and AstraZeneca’s TIDE

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

  • Pharma deals during June 2013 Pharma deals during June 2013

    Respiratory acquisitions. Continuing its run of deal activities, AstraZeneca (AZ) built on its respiratory interests with the acquisition of Pearl Therapeutics at a headline value of $1.15bn. ... AZ paid an initial $560m for Pearl's shares and a deferred

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Kala names Howard Rosen as chairman Kala names Howard Rosen as chairman

    Kala names Howard Rosen as chairman. He is former CEO of Pearl Therapeutics and VP at Gilead. ... His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics